208 related articles for article (PubMed ID: 32610185)
1. The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3β and MyD88/NF-κB signalling pathways.
Liu JH; Chen C; Li ZY; Zou ZM; Gao DC; Zhang X; Kuang XW; Sun ZH; Zheng WJ; Zhou P; Sun SR
Exp Cell Res; 2020 Sep; 394(2):112157. PubMed ID: 32610185
[TBL] [Abstract][Full Text] [Related]
2. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.
Xie L; Jiang FC; Zhang LM; He WT; Liu JH; Li MQ; Zhang X; Xing S; Guo H; Zhou P
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26712311
[TBL] [Abstract][Full Text] [Related]
3. A Novel Inhibitor of Homodimerization Targeting MyD88 Ameliorates Renal Interstitial Fibrosis by Counteracting TGF-β1-Induced EMT in Vivo and in Vitro.
Liu JH; He L; Zou ZM; Ding ZC; Zhang X; Wang H; Zhou P; Xie L; Xing S; Yi CZ
Kidney Blood Press Res; 2018; 43(5):1677-1687. PubMed ID: 30380557
[TBL] [Abstract][Full Text] [Related]
4. Short-term use of MyD88 inhibitor TJ-M2010-5 prevents d-galactosamine/lipopolysaccharide-induced acute liver injury in mice.
Ding Z; Du D; Yang Y; Yang M; Miao Y; Zou Z; Zhang X; Li Z; Zhang X; Zhang L; Wang X; Zhao Y; Jiang J; Jiang F; Zhou P
Int Immunopharmacol; 2019 Feb; 67():356-365. PubMed ID: 30583234
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of MyD88 homodimerization counteracts renal ischemia reperfusion-induced progressive renal injury in vivo and in vitro.
Zhang LM; Liu JH; Xue CB; Li MQ; Xing S; Zhang X; He WT; Jiang FC; Lu X; Zhou P
Sci Rep; 2016 Jun; 6():26954. PubMed ID: 27246399
[TBL] [Abstract][Full Text] [Related]
6. TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro.
Zou Z; Du D; Miao Y; Yang Y; Xie Y; Li Z; Zhou L; Zhang L; Zhou P; Jiang F
Int Immunopharmacol; 2020 Aug; 85():106648. PubMed ID: 32504998
[TBL] [Abstract][Full Text] [Related]
7. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
8. Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.
Li C; Zhang LM; Zhang X; Huang X; Liu Y; Li MQ; Xing S; Yang T; Xie L; Jiang FC; Jiang HY; He WT; Zhou P
Transplantation; 2017 Feb; 101(2):284-293. PubMed ID: 27607533
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway.
Han D; Wu G; Chang C; Zhu F; Xiao Y; Li Q; Zhang T; Zhang L
Oncotarget; 2015 Dec; 6(38):40907-19. PubMed ID: 26517513
[TBL] [Abstract][Full Text] [Related]
10. MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells.
Li S; Lu J; Chen Y; Xiong N; Li L; Zhang J; Yang H; Wu C; Zeng H; Liu Y
Cell Mol Immunol; 2017 Jul; 14(7):621-630. PubMed ID: 26996066
[TBL] [Abstract][Full Text] [Related]
11. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin.
Luo M; Hou L; Li J; Shao S; Huang S; Meng D; Liu L; Feng L; Xia P; Qin T; Zhao X
Cancer Lett; 2016 Apr; 373(1):1-11. PubMed ID: 26805761
[TBL] [Abstract][Full Text] [Related]
12. Ponicidin inhibits pro-inflammatory cytokine TNF-α-induced epithelial-mesenchymal transition and metastasis of colorectal cancer cells via suppressing the AKT/GSK-3β/Snail pathway.
Zhang Z; Xu J; Liu B; Chen F; Li J; Liu Y; Zhu J; Shen C
Inflammopharmacology; 2019 Jun; 27(3):627-638. PubMed ID: 30244296
[TBL] [Abstract][Full Text] [Related]
13. Beyond knockout: A novel homodimerization-targeting MyD88 inhibitor prevents and cures type 1 diabetes in NOD mice.
Zhang X; Xing S; Li M; Zhang L; Xie L; He W; Liu J; Chang S; Jiang F; Zhou P
Metabolism; 2016 Sep; 65(9):1267-77. PubMed ID: 27506734
[TBL] [Abstract][Full Text] [Related]
14. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Srivastava RK; Kurzrock R; Shankar S
Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
[TBL] [Abstract][Full Text] [Related]
16. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
17. Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.
Xing S; Zhang X; Huang X; Xie L; Jiang F; Zhou P
Leuk Lymphoma; 2019 Jun; 60(6):1528-1539. PubMed ID: 30501537
[TBL] [Abstract][Full Text] [Related]
18. Implication of myeloid differentiation factor 88 inhibitor TJ-M2010-5 for therapeutic intervention of hepatocellular carcinoma.
Liu J; Zhang X; Wang H; Zhang M; Peng Y; Li M; Xie L; Jiang F; Gong Y; Zhao Q; Zhou P
Hepatol Res; 2019 Oct; 49(10):1182-1194. PubMed ID: 31074165
[TBL] [Abstract][Full Text] [Related]
19. Nuclear receptor binding SET domain protein 1 promotes epithelial-mesenchymal transition in paclitaxel-resistant breast cancer cells via regulating nuclear factor kappa B and F-box and leucine-rich repeat protein 11.
Chen Y; Tang W; Zhu X; Zhang L; Zhu Y; Xiao H; Xu J; Fang Y; Li X; Tang C; Shi J
Bioengineered; 2021 Dec; 12(2):11506-11519. PubMed ID: 34905470
[TBL] [Abstract][Full Text] [Related]
20. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
